Heron Therapeutics Q2 Earnings Call Highlights

2 weeks ago 27

MarketBeat

Mon, August 10, 2026 astatine 9:04 AM CDT 6 min read

Key Points

Interested successful Heron Therapeutics, Inc.? Here are 5 stocks we similar better.
Second-quarter nett gross roseate to $37.7 million, but income of cardinal products fell abbreviated of management's expectations. ZYNRELEF income accrued 35% twelvemonth implicit twelvemonth to $11.1 million, APONVIE income roseate 74% to astir $4.2 million, portion CINVANTI income declined 10% to $21.8 million.
A Delaware tribunal ruling involving CINVANTI patents accrued the hazard of generic competition. Heron appealed, amended its recognition facility, made a $13.5 cardinal main payment, paused planned salesforce enlargement and withdrew its 2026 fiscal guidance.
Heron ended the 4th with $42.7 cardinal successful currency and investments, but pro forma currency fell to astir $28.5 cardinal aft the indebtedness payment. The institution is evaluating strategical alternatives and volition supply quarterly updates connected cash, spending and covenant compliance.

Heron Therapeutics (NASDAQ:HRTX) reported second-quarter nett gross of $37.7 million, up from $34.7 cardinal successful the archetypal 4th and $37.2 cardinal successful the comparable prior-year period, portion absorption said income of its cardinal products came successful beneath its interior expectations.

Chief Executive Officer Craig Collard said the company's acute-care franchise grew 44% twelvemonth implicit year, led by maturation successful postoperative symptom attraction ZYNRELEF and anti-nausea merchandise APONVIE. However, helium said some products expanded much dilatory than the institution had anticipated. Oncology merchandise CINVANTI posted sequential income maturation but remained down from a twelvemonth earlier amid branded competition.

→ Why the Landlord of the AI Boom Could Outlast the Chipmakers

Heron besides amended its recognition installation pursuing a June determination by the U.S. District Court for the District of Delaware involving definite patents covering CINVANTI. The institution has appealed the decision, paused a planned second-half salesforce expansion, withdrew its full-year outlook and said it is evaluating strategical alternatives.

Product Sales and Commercial Trends

Chief Operating Officer Mark Hensley said full acute-care income were $15.3 cardinal successful the 2nd quarter. ZYNRELEF generated $11.1 cardinal successful nett sales, up 9% sequentially from $10.2 cardinal and 35% from the prior-year quarter. Average regular units accrued 19% twelvemonth implicit year.

→ MarketBeat Week successful Review – 08/03 - 08/07

Hensley said the company's IGNITE 2.0 programme was progressive crossed 3,150 accounts, compared with 2,260 accounts nether IGNITE 1.0. He characterized ZYNRELEF adoption arsenic a "site-by-site, case-by-case adoption curve," saying the company's absorption is converting entree into cases and protocols astatine accounts wherever the merchandise is already available.

Read Entire Article